Basilea Pharmaceutica (OTCMKTS:BPMUF) Downgraded by Zacks Investment Research

Basilea Pharmaceutica (OTCMKTS:BPMUFGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. “

BPMUF stock remained flat at $$41.00 during midday trading on Tuesday. Basilea Pharmaceutica has a 12 month low of $41.00 and a 12 month high of $61.00. The firm has a fifty day simple moving average of $41.00 and a two-hundred day simple moving average of $42.10.

Basilea Pharmaceutica Company Profile (Get Rating)

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan.

Featured Articles

Get a free copy of the Zacks research report on Basilea Pharmaceutica (BPMUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.